United Kingdom

Almac Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 AACR Virtual Annual Meeting II

Lead Product(s): ADP-c165

Therapeutic Area: Oncology Product Name: ADP-c165

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 18, 2020

Details:

Presentations highlight significant new data for key oncology drug development programmes - USP7 small molecule inhibitors and ROR1 Protein: Drug Conjugates.

Ubiquigent

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Bristol-Myers Squibb

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 17, 2020

Details:

The collaboration, originally between Ubiquigent and Celgene, will allow Bristol Myers Squibb tocapitalise on the strength and breadth of Ubiquigent’s deubiquitylase (DUB) enzyme inhibitor drug discovery platform and expertise.

Vernalis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 15, 2020

Details:

The new 3 years research collaboration combines Vernalis’ strengths in structure and biophysics-based methods as part of the Vernalis Design Platform with the oncology expertise at Servier to enable to identify and enable new therapeutic targets.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Almac Group

Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 AACR Virtual Annual Meeting II

Ubiquigent

Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb

Vernalis

Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets